Roth Capital Downgrades Sciele Pharma (SCRX) to Hold
More News related to SCRX
- Top 15 For 2008 (No. 14): M&A Wreckage
- S&P Announces Changes to U.S. Indices: OII for CY, HPY for HRH, TKLC for SCRX; Updates Market Cap Guidelines
- Matrix USA Rating Changes 9/19
- Sciele Pharma (SCRX) and Addrenex Pharmaceuticals Report Positive Phase III Data on Clonicel
- Susquehanna Downgrades Sciele Pharma (SCRX) to Neutral
More News related to Downgrades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
Roth Capital downgrades Sciele Pharma (Nasdaq: SCRX) from Buy to Hold.
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular, Diabetes, Women's Health, And Pediatric treatment.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
